Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Cross-Platform Assessment Of Genomic Imbalance In Diffuse Large B-Cell Lymphoma Identifies Novel Candidate Loci and Genes With Prognostic Value and Roles In Lymphomagenesis

Lizalynn Dias, Ph.D., Venkata Thodima, Ph.D., Geetu Mendiratta, Ph.D., Guttapalli Asha, M.S., Camille Gonzalez, Jocelyn C. Maragulia, Andrew D. Zelenetz, MD, PhD, Julie Teruya Feldstein, MD, Raju S.K. Chaganti, PhD, FACMG, Jane Houldsworth, PhD

Blood (2013) 122 (21): 4259.

https://doi.org/10.1182/blood.V122.21.4259.4259

Published: 2013

Journal Articles

Cell Of Origin Does Not Affect Outcomes In Early Stage Non-Bulky Diffuse Large B-Cell Lymphoma Treated With Short-Course Combined Modality Therapy

Matthew A. Lunning, DO, Jocelyn C. Maragulia, BS, Anita Kumar, MD, Martin Bast, BS, Philip Bierman, MD, R. Gregory Bociek, MD, Julie M Vose, MD, MBA, James O. Armitage, MD, Steven M. Horwitz, MD, Andrew D Zelenetz, MD, PhD

Blood (2013) 122 (21): 3017.

https://doi.org/10.1182/blood.V122.21.3017.3017

Published: 2013

Journal Articles

Excellent Outcomes For Limited-Stage Diffuse Large B-Cell Lymphoma In The Rituximab Era: A Retrospective Analysis From Memorial Sloan-Kettering Cancer Center

Anita Kumar, MD, Jocelyn C Maragulia, Matthew A Lunning, DO, Craig H. Moskowitz, MD, Andrew D. Zelenetz, MD, PhD

Blood (2013) 122 (21): 3030.

https://doi.org/10.1182/blood.V122.21.3030.3030

Published: 2013

Journal Articles

Tumor Associated Macrophage Expression, CD163, Is Associated with Poorer Outcome in Diffuse Large B-Cell Lymphoma

Olga L. Bohn, MD, Jocelyn C. Maragulia, Hilda Crispin, Camille Gonzalez, Cornelius Miething, MD, Andrew D. Zelenetz, MD, PhD, Julie Teruya-Feldstein, MD

Blood (2012) 120 (21): 1583.

https://doi.org/10.1182/blood.V120.21.1583.1583

Published: 2012

Journal Articles

CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan.

Matthew A Lunning, DO, April Chiu, M.D., Julie Teruya Feldstein, MD, Jocelyn C. Maragulia, Alison Moskowitz, MD, Matthew J. Matasar, MD, MS, David J. Straus, MD, Ariela Noy, MD, Patricia L Myskowski, M.D., Andrew D. Zelenetz, MD, PhD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 2706.

https://doi.org/10.1182/blood.V120.21.2706.2706

Published: 2012

Journal Articles

Remission Duration ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose Therapy and Autologous Stem Cell Rescue.

Matthew A Lunning, DO, Jocelyn C Maragulia, Craig H. Moskowitz, MD, Matthew J. Matasar, MD, MS, Hugo Castro-Malaspina, MD, Sergio Giralt, MD, Andrew D. Zelenetz, MD, PhD, Craig S. Sauter, MD

Blood (2012) 120 (21): 3136.

https://doi.org/10.1182/blood.V120.21.3136.3136

Published: 2012

Journal Articles

Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity

Matthew P Salzberg, Jocelyn C Maragulia, Oliver W. Press, MD, PhD, Thomas M Habermann, MD, Julie M Vose, MD, MBA, Martin Bast, BS, Ranjana H. Advani, MD, Andrew M. Evens, DO, MSc, Nahida Islam, MD, John P. Leonard, MD, Peter Martin, MD, Peter J Hosein, MD, Andrew D Zelenetz, MD, PhD, Izidore S Lossos, MD

Blood (2012) 120 (21): 1618.

https://doi.org/10.1182/blood.V120.21.1618.1618

Published: 2012

Journal Articles

Semi-Quantitative Evaluation of Pre-Transplant FDG-PET in Relapsed and Refractory Hodgkin Lymphoma

Alison Moskowitz, MD, Jocelyn C Maragulia, Anita Kumar, MD, Craig H. Moskowitz, MD

Blood (2012) 120 (21): 2015.

https://doi.org/10.1182/blood.V120.21.2015.2015

Published: 2012

Journal Articles

Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL)

Craig H. Moskowitz, MD, Heiko Schoder, Paul Hamlin, MD, Jocelyn C Maragulia, Janelle Walkley, Andrew D. Zelenetz, MD, PhD

Blood (2012) 120 (21): 792.

https://doi.org/10.1182/blood.V120.21.792.792

Published: 2012

Journal Articles

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H. Moskowitz, Matt J. Matasar, Andrew D. Zelenetz, Stephen D. Nimer, John Gerecitano, Paul Hamlin, Steven Horwitz, Alison J. Moskowitz, Ariela Noy, Lia Palomba, Miguel-Angel Perales, Carol Portlock, David Straus, Jocelyn C. Maragulia, Heiko Schoder, Joachim Yahalom

Blood (2012) 119 (7): 1665–1670.

https://doi.org/10.1182/blood-2011-10-388058

Published: 2012

Journal Articles

Elderly Hodgkin Lymphoma At MSKCC From 1994–2008: Characteristics, Outcome and Risk Factor Analysis in 133 Patients,

Zachary H Word, MD, Jocelyn C Maragulia, Janelle Walkley, Daniel R. Smith, Paul Hamlin, MD

Blood (2011) 118 (21): 3648.

https://doi.org/10.1182/blood.V118.21.3648.3648

Published: 2011

Journal Articles

Six Cycles of ABVD and a Negative PET Scan Negates the Need for Radiologic Follow-up in Early Stage, Non-Bulky Hodgkin Lymphoma: MSKCC Retrospective Analysis

Sidonie K Hartridge-Lambert, MBBS, Heiko Schoder, MD, Remy C Lim, MD, Jocelyn C Maragulia, Carol S Portlock, MD

Blood (2011) 118 (21): 3139.

https://doi.org/10.1182/blood.V118.21.3139.3139

Published: 2011

Journal Articles

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Alison J. Moskowitz, Joachim Yahalom, Tarun Kewalramani, Jocelyn C. Maragulia, Jill M. Vanak, Andrew D. Zelenetz, Craig H. Moskowitz

Blood (2010) 116 (23): 4934–4937.

https://doi.org/10.1182/blood-2010-05-282756

Published: 2010

Journal Articles

Prognostic Significance of Positron Emission Tomography (FDG-PET) at Baseline and After 4 Cycles of R-CHOP in 75 Patients with Mantle Cell Lymphoma Treated with Intensive Chemotherapy and Autologous Stem Cell Rescue.

Rony Schaffel, MD, PhD, Craig H. Moskowitz, MD, Jocelyn C. Maragulia, Carol S. Portlock, MD, Cyrus V. Hedvat, MD, PhD, Andrew D. Zelenetz, MD, PhD

Blood (2009) 114 (22): 1226.

https://doi.org/10.1182/blood.V114.22.1226.1226

Published: 2009

Journal Articles

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Alison J. Moskowitz, MD, John Sweetenham, MD, Brian J. Bolwell, MD, Jocelyn C Maragulia, Jill M Vanak, ACNP, Craig H Moskowitz, MD, Stephen Smith, MD

Blood (2009) 114 (22): 3413.

https://doi.org/10.1182/blood.V114.22.3413.3413

Published: 2009

Journal Articles

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Craig H. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Paul A. Hamlin, Jr., MD, Steven M. Horwitz, MD, Ariela Noy, MD, Carol S. Portlock, MD, David J. Straus, MD, John Gerecitano, MD, PhD, Tarun Kewalramani, MD, Jill M. Vanak, ACNP, Jocelyn C. Maragulia, Joachim Yahalom, MD

Blood (2008) 112 (11): 775.

https://doi.org/10.1182/blood.V112.11.775.775

Published: 2008

Journal Articles

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Alison J. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Tarun Kewalramani, MD, Jill M Vanak, ACNP, Jocelyn c Maragulia, Joachim Yahalom, MD, Craig Moskowitz, MD

Blood (2008) 112 (11): 776.

https://doi.org/10.1182/blood.V112.11.776.776

Published: 2008

Journal Articles

Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival

Robert D. Rice, MSN, PhD(c), Craig H. Moskowitz, MD, Tarun Kewalramani, MD, Daniel O. Persky, MD, Brian T. Rafferty, Jocelyn C. Maragulia, Andrew D. Zelenetz, MD, PhD

Blood (2007) 110 (11): 1280.

https://doi.org/10.1182/blood.V110.11.1280.1280

Published: 2007

NARROW

Cross-Platform Assessment Of Genomic Imbalance In Diffuse Large B-Cell Lymphoma Identifies Novel Candidate Loci and Genes With Prognostic Value and Roles In Lymphomagenesis

Cell Of Origin Does Not Affect Outcomes In Early Stage Non-Bulky Diffuse Large B-Cell Lymphoma Treated With Short-Course Combined Modality Therapy

Excellent Outcomes For Limited-Stage Diffuse Large B-Cell Lymphoma In The Rituximab Era: A Retrospective Analysis From Memorial Sloan-Kettering Cancer Center

Tumor Associated Macrophage Expression, CD163, Is Associated with Poorer Outcome in Diffuse Large B-Cell Lymphoma

CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan.

Remission Duration ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose Therapy and Autologous Stem Cell Rescue.

Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity

Semi-Quantitative Evaluation of Pre-Transplant FDG-PET in Relapsed and Refractory Hodgkin Lymphoma

Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL)

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Elderly Hodgkin Lymphoma At MSKCC From 1994–2008: Characteristics, Outcome and Risk Factor Analysis in 133 Patients,

Six Cycles of ABVD and a Negative PET Scan Negates the Need for Radiologic Follow-up in Early Stage, Non-Bulky Hodgkin Lymphoma: MSKCC Retrospective Analysis

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Prognostic Significance of Positron Emission Tomography (FDG-PET) at Baseline and After 4 Cycles of R-CHOP in 75 Patients with Mantle Cell Lymphoma Treated with Intensive Chemotherapy and Autologous Stem Cell Rescue.

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only